Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
590
datasets available to search
ShareScore release 0.9.0
Dataset results
590 results for “muscular dystrophies.”
Kinematics and timed function tests of facioscapulohumeral muscular dystrophy and myotonic dystrophy
<p>This dataset contains <a href="https://www.opencap.ai/">OpenCap</a> kinematics (body position and joint angles), clinician-scored timed function tests (TFTs), and extracted biomechanical metrics for 129 individuals:</p> <ul> <li> <p>28 participants with facioscapulohumeral muscular dystrophy (FSHD)</p> </li> <li> <p>58 participants with myotonic dystrophy (DM)</p> </li> <li> <p>43 participants with typical movement</p> </li> </ul> <p>For more details, please see the accompanying paper (in submission):</p> <blockquote> <p><strong>Video-based biomechanical analysis captures disease-specific movement signatures of different neuromuscular diseases</strong></p> <p>Parker S. Ruth*, Scott D. Uhlrich*, Constance de Monts, Antoine Falisse, Julie Muccini, Sydney Covitz, Shelby Vogt-Domke, John Day, Tina Duong,† Scott Delp†</p> <p>*Contributed equally, †Contributed equally</p> </blockquote>
Diagnostic strategies for muscular dystrophies: a Cross-Sectional Study
<p>Datos obtenido producto de un estudio de corte transversal con el fin de establecer la prevalencia de base hospitalaria en distrofias musculares, a través de un diseño de muestreo en fases.</p>
Multiomics Analysis of the mdx/mTR Mouse Model of Duchenne Muscular Dystrophy
<p>This dataset contains RNA sequencing, proteomics, metabolomics, lipidomics, primer sequence, and Ingenuity Pathway Analysis data for a study evaluating differences between the transcriptome, proteome, metabolome, and lipidome of lower limb muscles of mdx/mTR (Jackson Labs strain 023535) and wild-type C57BL/6J (Jackson Labs strain 000664) mice. Updated from previous submission, DOI: 10.5281/zenodo.3370799.</p>
Dateset related to article "Cytokines as potential biomarkers of disease clinical course in muscular dystrophies "
<p>This database includes a comprehensive profile of circulating pro- and anti-inflammatory molecules (cytokines, chemokines and growth factors) obtained from a group of 53 patients with muscular laminopathy, 10 with non-muscular laminopathy, 22 with other muscular disorders and 35 healthy controls. Data obtained by Luminex multiple immune-assay identify TGF-b2, IL-17 and G-CSF as potential biomarkers in discriminating between muscle-related laminopathy and healthy subjects. The different expression of IL-1b, IL-4 and IL-8 among the different forms of laminopathy provides a new hint for the understanding of the pathogenic mechanisms underlying the diverse phenotypes caused by <em>LMNA</em> mutations.</p>
Novel DMD mouse model carrying a multi-exonic Dmd deletion exhibit progressive muscular dystrophy and early-onset cardiomyopathy
Duchenne muscular dystrophy (DMD) is a life-threatening neuromuscular disease caused by the lack of dystrophin, resulting in progressive muscle wasting and locomotor dysfunctions. By adulthood, almost all patients also develop cardiomyopathy, which is the primary cause of death in DMD. While there has been extensive effort in creating animal models to study treatment strategies for DMD, most fail to recapitulate the complete skeletal and cardiac disease manifestations that are presented in affected patients. Here, we generated a mouse model mirroring a patient deletion mutation of exons 52-54 (<i>Dmd &[Delta]52-54</i>). The <i>Dmd &[Delta]52-54</i> mutation led to the absence of dystrophin, resulting in progressive muscle deterioration with weakened muscle strength. Moreover, <i>Dmd &[Delta]52-54</i> present with early-onset cardiomyopathy which is absent in current pre-clinical dystrophin deficient mouse models. Therefore, <i>Dmd &[Delta]52-54</i> presents itself as an excellent pre-clinical model to evaluate the impact on skeletal and cardiac muscles for both mutation dependent and independent approaches.
MD-Vibe Dataset: Footstep-Induced Floor Vibration Data for Functional Gait Assessment of Individuals with Muscular Dystrophy
<p>The purpose of this dataset is to evaluate the performance of floor vibration sensing in tracking the progression of muscular dystrophy through individuals’ gait patterns. We recruited human subjects (N=36) and conducted experiments at Stanford University and Nationwide Children's Hospital in Columbus, Ohio, with healthy human subjects (N=21) and children with MD (N=15).</p> <p> </p> <p>The experiments consist of two phases - Phase 1 is a pilot study to test the feasibility of floor vibration sensing in capturing gait characteristics in lab settings; Phase 2 has two hospital studies to evaluate our sensing method in real life. This dataset consists of floor vibration data (vertical velocity of floor vibration) induced by 9 healthy subjects’ footsteps from these two phases, named <strong>lab data.zip</strong>, <strong>hospital data 1.zip</strong>, and <strong>hospital data 2.zip</strong>, respectively. The complete dataset requires a data-sharing agreement with Nationwide Children's Hospital.</p> <p> </p> <p>The custom coding scripts (in MATLAB and Python) to process the data are included in the <strong>code.zip</strong> file, which includes 3 processing steps: 1) Preprocessing and Footstep Detection, 2) Feature Extraction, and 3) Model Prediction, the scripts of each step are grouped into a folder with their corresponding names. Detailed function descriptions are included in the scripts.</p> <p> </p> <p>The footstep-induced structural vibration data is stored as both raw data and as individual footsteps. The raw data files start with “raw_”, each consisting of a series of consecutive footsteps (see the sample plot). The individual footstep data files start with “detected_steps_”, each consisting of one single footstep detected from the raw data. The dataset is stored in MAT file format that can be accessed through MATLAB.</p> <p> </p> <p>The sensing unit consists of 5 components: 1) the geophone (SM-24), 2) the amplification module, 3) the processor board, 4) the data acquisition module (NI-Daq), and 5) the power cables. The sensing unit converts the structural vibration velocity into voltage records. The sampling frequency is 500 Hz for the lab study and 25600 Hz for the hospital studies.</p> <p> </p> <p>The experiment setup, sample data plot, and code usage can be found in <strong>Dataset Description.pdf</strong>. For more details about the hospital studies, please refer to the MD-Vibe paper at the following link: <a href="https://doi.org/10.1145/3410530.3414610">https://doi.org/10.1145/3410530.3414610</a></p> <p> </p> <p>Please cite this dataset as:</p> <p>Yiwen Dong, Megan Iammarino, Jingxiao Liu, Jesse Codling, Jonathon Fagert, Mostafa Mirshekari, Linda Lowes, Pei Zhang, and Hae Young Noh. 2023. The MD-Vibe Dataset: Footstep-Induced Floor Vibration Data for Functional Gait Assessment of Individuals with Muscular Dystrophy. Zenodo, DOI: <a href="https://doi.org/10.5281/zenodo.8125704">https://doi.org/10.5281/zenodo.8125744</a></p> <p> </p> <p>Yiwen Dong, Joanna Jiaqi Zou, Jingxiao Liu, Jonathon Fagert, Mostafa Mirshekari, Linda Lowes, Megan Iammarino, Pei Zhang, and Hae Young Noh. 2020. MD-Vibe: physics-informed analysis of patient-induced structural vibration data for monitoring gait health in individuals with muscular dystrophy. In Adjunct Proceedings of the 2020 ACM International Joint Conference on Pervasive and Ubiquitous Computing and Proceedings of the 2020 ACM International Symposium on Wearable Computers (UbiComp-ISWC '20). Association for Computing Machinery, New York, NY, USA, 525–531. <a href="https://doi.org/10.1145/3410530.3414610">https://doi.org/10.1145/3410530.3414610</a></p>
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
ClinicalTrials.gov study NCT01826487. IPD Sharing: NO. Countries: 18. Publications: 4.
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
ClinicalTrials.gov study NCT02606136. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT04281485. IPD Sharing: YES. Countries: 15. Publications: 0.
An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT02907619. IPD Sharing: YES. Countries: 5. Publications: 1.
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
ClinicalTrials.gov study NCT05397470. IPD Sharing: YES. Countries: 9. Publications: 4.
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT02310763. IPD Sharing: YES. Countries: 8. Publications: 8.
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT03406780. IPD Sharing: NO. Countries: 1. Publications: 1.
Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT01521546. IPD Sharing: Not stated. Countries: 1. Publications: 2.
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
ClinicalTrials.gov study NCT02760277. IPD Sharing: Not stated. Countries: 6. Publications: 3.
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT02354352. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
ClinicalTrials.gov study NCT03362502. IPD Sharing: NO. Countries: 1. Publications: 4.
Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)
ClinicalTrials.gov study NCT00759876. IPD Sharing: NO. Countries: 1. Publications: 2.
Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study
ClinicalTrials.gov study NCT02780492. IPD Sharing: YES. Countries: 3. Publications: 3.
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
ClinicalTrials.gov study NCT03769116. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.